Introduction
Despite recent advances in treatment strategies using dose-intensified regimens and new molecular-targeted compounds, multiple myeloma (MM) remains incurable (Kyle et al., 2003) . Most patients with MM eventually become resistant to the treatment and die of disease progression within 10 years. To improve the prognosis of myeloma patients, it is essential to overcome drug resistance (DR).
MM is characterized by the infiltration and growth of malignant plasma cells in the bone marrow (BM) microenvironment. MM cells localize within the BM through the interaction of adhesion receptors with their ligands on BM stromal cells and extracellular matrix proteins (Hideshima et al., 2007) . It has been demonstrated that MM cells in the BM microenvironment are much less sensitive to chemotherapeutic agents (Damiano et al., 1999; Nefedova et al., 2003) . This type of DR has been termed cell adhesion-mediated DR (CAM-DR), which is believed to play a crucial role in both de novo and acquired DR in MM patients (Damiano et al., 1999) . Despite extensive investigations, the adhesion molecules critical for CAM-DR in MM have not been identified yet.
The proteasome inhibitor bortezomib (Velcade, formerly known as PS-341) has shown a clinical activity in patients with relapsed MM (Richardson et al., 2003 (Richardson et al., , 2005 , and will be applied for the treatment of other hematologic malignancies and solid tumors in the near future (Fisher et al., 2006; Davies et al., 2007) . Bortezomib is a reversible inhibitor of the 26S proteasome complex, which catalyses ubiquitin-dependent protein degradation. Inhibition of this complex ultimately leads to modulation of the abundance and functions of many intracellular proteins in bortezomibtreated cells (Hideshima et al., 2001) . Among them, the multifunctional transcription factor nuclear factorkappa B (NF-kB) is considered the most relevant target in MM, because recent genome-wide approaches revealed that this factor is frequently activated in MM cells by mutations of the components of the NF-kB signaling cascade (Annunziata et al., 2007; Keats et al., 2007) . Given the wide spectrum of transcriptional targets of NF-kB including adhesion molecules and the IAP family of apoptosis inhibitors (Dolcet et al., 2005) , it is reasonable to speculate that CAM-DR of MM is mediated by NF-kB and could be overcome by bortezomib. To date, however, such possibilities have not been investigated.
In this study, we first attempted to identify the adhesion molecules responsible for CAM-DR in MM. By functional screening using the lentiviral short hairpin/small interfering RNA (shRNA/siRNA) system, we identified VLA-4 as a critical molecule for the induction of CAM-DR in MM cells. Furthermore, we found a novel and unique property of bortezomib to overcome CAM-DR by downregulating the expression of CD49d, a subunit of VLA-4. These results suggest that bortezomib enhances the effects of conventional anti-myeloma agents by overcoming VLA-4-mediated CAM-DR, and bortezomib-based combination chemotherapy can improve the treatment outcome of patients with MM.
Results

Surface expression of adhesion molecules on MM cells
In an initial effort to identify the molecules responsible for CAM-DR, we screened for the expression of adhesion molecules on MM cells using flow cytometry. By referring to previous studies (Tatsumi et al., 1996; Cook et al., 1997) , we selected the molecules to be checked as follows: CD11a (lymphocyte functionassociated antigen-1 (LFA-1)), CD18 (b2-integrin), CD22, CD29 (b1-integrin), CD40, CD44 (homingassociated cell adhesion molecule (HCAM)), CD49d (a4-integrin, a subunit of VLA-4), CD49e (a5-integrin, a subunit of VLA-5), CD54 (intercellular adhesion molecule-1 (ICAM-1)), CD56 (neural cell adhesion molecule (NCAM)), CD138 (syndecan-1) and CD184 (CXC chemokine receptor-4 (CXCR4)). We examined the expression of these molecules in four bona fide human MM cell lines (KHM-1B, KMS12-BM, RPMI8226 and U266) and normal plasma cells from healthy volunteers. As shown in Figure 1a , MM cell lines readily expressed CD29, CD44, CD49d, CD54, CD138 and CD184, whereas CD22 was barely detectable. The expression of CD11a, CD18, CD40, CD49e and CD56 was highly variable among cell lines. Normal plasma cells expressed the same set of molecules as MM cell lines except CD22, but their expression levels were generally lower than those of MM cells. It is of note that RPMI8226 showed a slightly different pattern from other cell lines: it expressed CD29, CD44 and CD49d lower but CD49e higher. Overall, we identified CD29, CD44, CD49d, CD54, CD138 and CD184 as major adhesion molecules expressed on MM cell lines.
To further elucidate the expression pattern of adhesion molecules in MM, we screened for their expression on primary MM cells. As CD138 is commonly used as a specific marker for myeloma cells in BM specimens, we detected the expression of CD44, CD49d and CD54 in CD138-positive fractions in BM-mononuclear cells (MNCs) from 18 patients with MM by dual staining on flow cytometry. As shown in Figure 1b , CD44, CD49d and CD54 were moderately to markedly expressed in all patients involved in this study. The proportions of positive cells were 52.8±37.7% for CD44, 57.0±31.6% for CD49d and 56.8 ± 30.9% for CD54 in the CD138-positive fractions (CD138 positivity was 60.0 ± 31.0% in the entire fraction). This pattern closely resembled that of the cell lines. On the basis of these results, we focused on CD29 (b1-integrin), CD44 (HCAM), CD49d (a4-integrin), CD54 (ICAM-1), CD138 (syndecan-1) and CD184 (CXCR4) to determine the functional adhesion molecules in MM in further studies.
Establishment of the in vitro culture system for the assessment of CAM-DR of MM cells To investigate the involvement of these adhesion molecules in CAM-DR of MM cells, we established a culture system recapitulating CAM-DR in vitro. As described in Materials and methods, green fluorescent protein (GFP)-expressing MM cells were added into culture dishes with (co-culture) or without (stroma free) a preseeded UBE6T-7 stromal cell line, and cultured for 2 days in the absence or presence of four anti-myeloma drugs. We determined the cytotoxic effects of the drugs on MM cells specifically by measuring annexin-V positivity in GFP-positive fractions on flow cytometry. Figure 2a shows the representative results of KMS-12BM cells treated with suboptimal doses of each drug determined in pilot experiments: bortezomib 5 nM, vincristine 1 nM, doxorubicin 100 nM and dexamethasone 50 nM (Supplementary Figure S1) . All of them are lower than clinically achievable concentrations in vivo according to recent clinical trials (Fisher et al., 2006; Davies et al., 2007) . These drugs were capable of inducing apoptosis in more than 20% of KMS-12BM cells under stroma-free condition. In addition, we stained cells with propidium iodide to estimate the contribution of other forms of cell death to the cytotoxicity of these drugs. The percentages of dead cells obtained with propidium iodide staining were almost equal to or slightly higher than those obtained with annexin-V staining, implying that the major form of cell death is apoptosis (Supplementary Figure S2A) . The cytotoxic effects were markedly diminished under the co-culture condition, suggesting that CAM-DR was successfully reproduced in our system (Figure 2a ; Supplementary Figure S2 determine which adhesion molecule(s) is important for CAM-DR in MM cells.
Reversal of CAM-DR by shRNA/siRNA-and blocking antibody-mediated knockdown of VLA-4 in MM cells To investigate which adhesion molecule(s) is critical for the acquisition of CAM-DR in MM cells, we performed loss-of-function analyses for CD44 (HCAM), CD49d (a4-integrin), CD54 (ICAM-1), CD138 (syndecan-1) and CD184 (CXCR4) using the shRNA/siRNA lentivirus system . Because CD29 (b1-integrin) is heterodimerized with CD49d and functions as VLA-4 (a4b1-integrin) on MM cells, we could achieve loss of function of VLA-4 by solely targeting CD49d. As shown in Figure 3a , shRNA/siRNA expression vectors were constructed by inserting chemically synthesized oligonucleotides containing target sequences (Supplementary Table S2 ) into pLL3.7 vector, and their inhibitory activities were checked in KMS-12BM cells (data not shown). Constructs with the strongest activities were transfected into three MM cell lines along with sh controls, and a specific reduction of target expression was confirmed (Figure 3b ; Supplementary Figure S3 ). Overall, we established 15 sublines in which the expression of individual adhesion molecules was markedly downregulated, and examined the levels of CAM-DR to four anti-myeloma drugs. To quantitatively assess the contribution of each molecule to CAM-DR, we defined the ratio of annexin-V reactivity of GFP-positive cells under the co-culture condition to that under the stroma-free condition as a reversal of CAM-DR. The reversal of CAM-DR to bortezomib was detectable in CD49d-knockdown sublines of all three cell lines, whereas no reversal was observed in sublines carrying shRNA/siRNA against other four adhesion molecules and inactive sh controls (Figure 3c ; Supplementary Table S3 ). In addition, we performed the same experiments using vincristine and dexamethasone in KMS-12BM sublines. The CAM-DR to vincristine and dexamethasone was also reversed by knockdown of CD49d but not other four molecules (Figure 3d ; Supplementary Table S4) . It is of note that the reversal of CAM-DR to either vincristine or dexamethasone was at the almost equal level to that to bortezomib in CD49d-knockdown sublines (compare Figures 3c and  d) . In view of the fact that bortezomib is relatively resistant to CAM-DR (see Figure 2 and Supplementary  Table S1 ), this implies that bortezomib modulates the expression of CD49d in MM cells (discussed later). Furthermore, we confirmed the importance of CD49d in CAM-DR using adhesion-blocking antibodies instead of shRNA/siRNA introduction. We used specific antibodies against CD44, CD49d, CD54 and CD184 to revert CAM-DR, but were not able to test an anti-CD138 antibody because it is not commercially available. MM cells were pretreated with these antibodies, cultured with or without stromal cells in the presence of bortezomib, and subjected to flow cytometric analysis for annexin-V reactivity. As shown in Figure 4 and Supplementary Table S5, significant reversal of CAM-DR was achieved by treatment with anti-CD49d (a4-integrin) and anti-CD54 (ICAM-1) antibodies in KMS-12BM and U266 cells, albeit the effect of the former was much stronger. The effectiveness of anti-CD54 may stem from its effects on stromal cells, because previous studies revealed that CD54 was expressed on BM stromal cells (Corso et al., 2005) . In contrast, the other antibodies failed to revert CAM-DR in KMS-12BM and U266 cells. Unexpectedly, CAM-DR was not affected by any antibodies in RPMI8226 cells, probably due to the relatively low expression of CD49d. Although there was slight discrepancy between the results obtained with shRNA/siRNA and adhesion-blocking antibodies, our data clearly indicate that VLA-4, a heterodimer of CD49d and CD29, is the most important adhesion molecule for CAM-DR in MM cells.
Downregulation of CD49d expression by bortezomib
It is tempting to speculate that bortezomib modulates the expression of CD49d in MM cells from our two findings: the relative resistance of bortezomib to CAM-DR (see Figure 2 ) and equal reversal of CAM-DR to all three drugs on disruption of VLA-4 signaling (see Figure 3 ). In support of this view, Duechler et al. (2005) reported that bortezomib decreased the surface expression of CD23 in chronic lymphocytic leukemia. Therefore, we investigated the effect of bortezomib and other anti-myeloma drugs on the expression of adhesion molecules on MM cell lines. Figure 5a and Supplementary Figure S4 show the representative data of flow cytometric analysis of viable KMS-12BM cells before and after treatment with bortezomib. Untreated KMS-12BM cells strongly expressed CD29, CD44, CD49d, CD54, CD138 and CD184. Bortezomib did not affect the expression levels of CD29, CD44, CD54, CD138 and CD184, but decreased the expression of CD49d from 99.4±0.1 to 34.5±0.9% (n ¼ 3, Po0.05). Bortezomibinduced downregulation of CD49d expression was similarly observed in RPMI8226 and U266 cells: from 33.2 ± 0.6 to 12.4 ± 1.9% in RPMI8226 cells (n ¼ 3, Po0.05) and from 99.4±0.04 to 74.3±4.1% in U266 cells (n ¼ 3, Po0.05). Furthermore, we confirmed bortezomib-mediated reduction of CD49d expression by immunoblotting using whole-cell lysates (Figure 5b ), semiquantitative reverse transcription (RT)-PCR ( Figure 5c ) and real-time quantitative RT-PCR (Figure 5d ), suggesting that this phenomenon takes place at mRNA levels. In striking contrast, other antimyeloma drugs, such as vincristine, doxorubicin and dexamethasone, did not affect the expression of CD49d (Figure 5e ; Supplementary Figure S4 ) and other adhesion molecules (Supplementary Figure S5) in any cell lines examined. The specific reduction of CD49d expression by bortezomib may underlie the relative resistance of the drug to CAM-DR in MM cells.
Next, we investigated the mechanisms by which bortezomib suppresses the expression of CD49d mRNA. For this purpose, we directly inhibited NF-kB activity in KMS-12BM cells using SN-50 peptide, which interferes with nuclear translocation of p50 by binding to its nuclear localization sequence (Lin et al., 1995) . Surface expression of CD49d was not affected by the (c) MM cell lines stably transfected with shRNA vectors were cultured with 2 nM bortezomib in the presence (co-culture) or absence (stroma free) of stromal cells. After 48 h, MM cells were harvested by pipetting, stained with annexin-V/PE, and subjected to flow cytometric analysis. The Y axis shows the reversal of CAM-DR as a ratio (%) of annexin-V positivity under co-culture vs stroma-free conditions. When annexin-V reactivity under co-culture condition is equal to that of stroma-free condition, the reversal of CAM-DR is 100%. The means±s.d. (bars) of three independent experiments are shown. The P-values were calculated by Student's t-test. *Po0.05 against the sh control. (d) KMS-12BM sublines stably transfected with shRNA vectors were cultured with 1 nM vincristine (VCR) or 50 nM dexamethasone (Dexa) in the presence (co-culture) or absence (stroma free) of stromal cells. After 48 h, the reversal of CAM-DR was examined as described above. *Po0.05 against the sh control.
Bortezomib overcomes drug resistance in myeloma K Noborio-Hatano et al p50 inhibitory peptide, suggesting that bortezomibmediated downregulation of CD49d is not a direct consequence of the inhibition of NF-kB activity (Supplementary Figure S6) .
The reversal of CAM-DR to conventional anti-myeloma drugs by pretreatment with bortezomib
Given that bortezomib decreases the expression of CD49d, which plays a crucial role in CAM-DR, pretreatment of MM cells with bortezomib could overcome CAM-DR to conventional anti-myeloma drugs. Finally, we tested this hypothesis using the coculture system for CAM-DR. MM cells were pretreated with bortezomib for 24 h, followed by exposure to either vincristine or dexamethasone for additional 24 h in the presence or absence of stroma cells. Pretreatment with bortezomib significantly reversed CAM-DR to both vincristine and dexamethasone in all three cell lines tested (Figure 6a ), which coincided with the detachment of myeloma cells (Figure 6b ). In particular, CAM-DR to VCR was almost completely inhibited in KMS-12BM and RPMI8226 cells: reversal ratios were 87.4±3.2 and 104.6 ± 19.4%, respectively. In U266 cells, the effects of bortezomib were moderate but significant. This may be attributable to the relatively weak effects of bortezomib on CD49d expression in U266 cells (see Figure 5d ). It should be emphasized that the combination of bortezomib with either vincristine or dexamethasone at the doses used in this experiment did not show additive effects under stroma-free condition (data not shown).
Discussion
In this study, we have clearly demonstrated that VLA-4, a heterodimer of CD49d/CD29, plays a critical role in CAM-DR of MM using a unique strategy involving myeloma cell lines in which individual adhesion molecules were stably knocked down by the aid of shRNA. In support of our finding, several studies described the roles of VLA-4 in the pathophysiology of MM. For example, CD29-mediated adhesion of MM cells to fibronectin upregulated the expression of the CDK inhibitor p27 and induced NF-kB activation, both of which confer CAM-DR to MM (Chauhan et al., 1996; Hazlehurst et al., 2000; Landowski et al., 2003) . Two independent groups reported that administration of anti-CD49d antibody suppressed the growth of MM cells in murine xenograft models Olson et al., 2005) . In line with these experimental findings, Schmidmaier et al. (2006) found that MM patients with primary multidrug resistance showed significantly higher concentrations of serum VLA-4 and ICAM-1 than responders. The involvement of VLA-4 in CAM-DR was also demonstrated in AML by the seminal study of Matsunaga et al. (2003) , in which the combination of cytosine arabinoside and antiCD49d antibody achieved a 100% survival rate in mice transplanted with AML cells. These findings strongly suggest that VLA-4-mediated signaling is important for the development of DR in MM and AML cells both in vitro and in vivo.
In addition, we obtained evidence indicating that bortezomib can overcome CAM-DR by selectively downregulating CD49d expression in myeloma cells. This ability was specific for bortezomib and was not observed in other commonly used anti-myeloma drugs such as vincristine, doxorubicin and dexamethasone. Moreover, we have found that bortezomib represses the expression of CD49d at mRNA levels. Regarding the mechanisms of this phenomenon, the direct involvement of NF-kB is unlikely because the p50 inhibitory peptide anti-CD54 anti-CD184 * * * * Figure 4 Effects of blocking antibodies against adhesion molecules on adhesion-mediated drug resistance (CAM-DR) in multiple myeloma (MM) cells. MM cell lines were treated with either antibodies against CD44, CD49d, CD54 and CD184 or isotype-matched controls (iso. cont.) at 10 mg/ml at 37 1C for 1 h. After treatment, cells were cultured with 2 nM bortezomib in the presence (co-culture) or absence (stroma free) of stromal cells for 48 h. The reversal of CAM-DR was determined as described in the legend of Figure 3 . The means±s.d. (bars) of three independent experiments are shown. The P-values were calculated by Student's t-test. *Po0.05 against isotype-matched controls.
[CD49d] (α4-integrin) did not downregulate the expression of CD49d in KMS-12BM cells, in which NF-kB is constitutively activated through the classical pathway (Keats et al., 2007) . The CD49d promoter contains canonical binding sites for Sp1, Ets and WT1 (Rosen et al., 1994; Zutter et al., 1997; Kirschner et al., 2006) . We are currently investigating whether these factors are implicated in bortezomib-mediated downregulation of CD49d mRNA expression.
The reversal of CAM-DR by bortezomib may underlie its broad range of synergy with other anticancer drugs as recently described (Horton et al., 2006; Noborio-Hatano et al., 2007) . Unfortunately, severe pulmonary complications have been reported in Japanese patients treated with bortezomib (Miyakoshi et al., 2006) . Dose reduction by drug combination is one method to minimize side effects of bortezomib. Furthermore, it has been shown that the contact of MM cells with BM stromal cells through VLA-4/vascular cell adhesion molecule-1 (VCAM-1) interactions enhanced the production of osteoclastogenesis factors and that disruption of this cell-to-cell contact suppressed the development of osteoclastic osteolysis associated with MM (Michigami et al., 2000; Pearse et al., 2001) . As bortezomib can suppress CD49d expression, this drug may also be effective for the amelioration of bone lesions in MM.
Although our findings provide rationale for safe and effective treatment strategies for refractory myeloma, further investigation is required to define suitable combinations involving not only conventional antimyeloma drugs but also new drugs such as lenalidomide. Previous studies revealed that both bortezomib and dexamethasone induced apoptosis primarily through caspase-9, whereas lenalidomide did so through caspase-8 (Mitsiades et al., 2002) . Indeed, we found that caspase-8 was not activated in MM cells by the drugs used in this study (data not shown). On the basis of these findings, the combination of lenalidomide with either bortezomib or dexamethasone is expected to trigger dual apoptotic signaling pathways and reverse DR, which results in the achievement of clinical responses in patients resistant to single agents. In support of this view, we have reported that bortezomib is effective for myeloma patients refractory to thalidomide therapy (Takatoku et al., 2004) . The combination of bortezomib with other antimyeloma drugs, including thalidomide and its derivatives, is effective for overcoming CAM-DR and may improve the prognosis of MM patients.
Materials and methods
Cells and cell culture
We used four bone fide human MM cell lines, KHM-1B, KMS-12BM, RPMI8226 and U266, in this study (Drexler et al., 2003) . These cell lines were purchased from the Health Science Research Resources Bank (Osaka, Japan), and maintained in RPMI1640 medium (Sigma Co., St Louis, MO, USA) supplemented with 10% heat-inactivated fetal calf serum (Sigma Co.,) and antibiotics. Human BM-derived stromal cell line UBE6T-7 (Mori et al., 2005) , which was transduced with a human telomerase catalytic protein subunit, was kindly provided by Dr Akihiro Umezawa (National Research Institute for Child Health and Development, Tokyo, Japan), and used as stromal cells in co-culture experiments. Primary MM cells were isolated from the BM of patients at the time of diagnostic procedure. CD38-positive/CD45-low or negative (CD38 þ /CD45 lo/neg ) cells were purified from the BM of healthy volunteers, and used as normal plasma cells. Informed consent was obtained in accordance with the Declaration of Helsinki, and the protocol was approved by the Institutional Review Board.
Drugs and adhesion-blocking antibodies Bortezomib (Velcade) was provided by Millennium Pharmaceuticals (Cambridge, MA, USA). We used vincristine (Shionogi Co. Ltd., Tokyo, Japan), doxorubicin (Meiji Co. Ltd., Tokyo, Japan) and dexamethasone (Sigma Co.) as conventional anti-myeloma drugs. All drugs were dissolved in RPMI1640 medium at appropriate concentrations and stored at À80 1C until use. We used the following adhesionblocking antibodies in co-culture experiments: anti-CD44 (clone Hermes-1; Endogen, Rockford, IL, USA), anti-CD49d (2B4; R&D Systems, Minneapolis, MN, USA), anti-CD54 (Ab-2; Labvision Corp., Fremont, CA, USA), anti-CD184 (44717.111; R&D Systems), and mouse or rat IgG isotype controls (eBioscience, San Diego, CA, USA). Blocking experiments were performed as described earlier. In brief, 1 Â 10 6 of MM cells were incubated with 10 mg/ml antibodies or isotype-matched controls in 100 ml of RPMI1640 medium for 1 h, then diluted to 2 Â 10 5 cells/ml in complete medium, and added into culture wells preseeded with stromal cells (Matsunaga et al., 2003) .
Flow cytometric analysis of adhesion molecules
Cells were stained with specific monoclonal antibodies and analysed using BD-LSR or FACSaria flow cytometer (Becton Dickinson, Oxford, UK) as described earlier (Kikuchi et al., 2005) . The antibodies used were phycoerythrin (PE)-conjugated antibodies against CD11a (clone HI 111; BioLegend, San Diego, CA, USA), CD29 (4B4; Beckman Coulter, Fullerton, CA, USA), CD18 (6.7), CD22 (HIB22), CD29 (HUTS-21), CD49e (IIA1), CD56 (B159), CD138 (MI15) and CD184 (12G5) (all from Becton Dickinson), CD40 (5C3), CD44 (G44-26), CD49d (9F10) and CD54 (HA58) (all from eBioscience), allophycocyanine-conjugated antibodies against CD38 (HB7; Becton Dickinson) and PE-Cy7-conjugated antibodies against CD45 (2D1; Becton Dickinson).
Cell proliferation assay
Cell proliferation was monitored using Cell Counting Kit-8 (Dojin Chemical, Tokyo, Japan). In brief, cells were seeded in 96-well flat-bottomed microplates at a density of 5 Â 10 4 per well and incubated with or without anti-myeloma drugs for 48 h at 37 1C. After incubation, 10 ml of WST-8 solution was added to each well at a final concentration of 1 mg/ml. Cells grown in complete medium alone were used as controls. After incubation at 37 1C for 4 h, absorbance was measured at a wavelength of 450 nm using a microplate reader.
Co-culture of MM cells with stromal cells and the assessment of cell death For co-culture experiments, we established GFP-expressing MM cell lines by transfecting GFP expression plasmids to distinguish MM cells from stromal cells. UBE6T-7 stromal cells were seeded in 48-well plates to near confluence. After stromal cells were washed once with fresh medium, GFPtransduced MM cells were added to the plates and cultured in the absence or presence of anti-myeloma drugs. After 48 h, the cells were harvested by pipetting, washed with phosphatebuffered saline, and stained with PE-conjugated annexin-V (annexin-V/PE) (Biovision, Mountain View, CA, USA). Cell death/apoptosis was judged by annexin-V reactivity in GFPpositive populations using flow cytometer (Yanamandra et al., 2006) . Construction and production of lentiviral shRNA/siRNA expression vectors We used a lentiviral shRNA/siRNA expression vector pLL3.7. for knockdown of adhesion molecules. siRNA target sequences were designed to be homologous to wild-type cDNA sequences. Oligonucleotides were chemically synthesized, annealed, terminally phosphorylated and inserted into pLL3.7 vector. Oligonucleotides containing siRNA target sequences were shown in Supplementary Table S1 . Ineffective sequences were used as sh controls. These vectors were co-transfected into 293FT cells with packaging plasmids (purchased from Invitrogen, Carlsbad, CA, USA). Infectious lentiviruses in culture supernatants were harvested, concentrated and infected as described earlier . Lentiviruses were then added into cell suspensions in the presence of 8 mg/ml polybrene, and transduced for 24 h. Transduction efficiencies were monitored by GFP expression using a flow cytometer.
Immunoblotting
Immunoblotting was carried out according to the standard method using the following antibodies: anti-CD49d (Novus Biologicals, Littleton, CO, USA), anti-CD54 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-caspase-8, anticaspase-9 (Becton Dickinson) and anti-GAPDH (Santa Cruz Biotechnology) (Odgerel et al., 2008) .
PCR
We performed semiquantitative RT-PCR and real-time quantitative RT-PCR to estimate the expression of CD49d at mRNA levels. For the former, PCR amplification was carried out with 1 ml of cDNA solution (corresponding to 50 ng total RNA) in a 50-ml reaction mixture containing 5 U of Taq polymerase, 10 mM Tris-HCl (pH 8.5), 50 mM KCl, 1.5 mM MgCl 2 and 100 mM dNTPs in the presence of specific primer pairs (200 nM each) as follows; CD49d, forward: 5 0 -GGATGT GAACAGAAAGGCAGA-3 0 , reverse: 5 0 -GCCAGTGTTGA TAACATGGAAA-3 0 ; GAPDH (internal control), forward: 5 0 -CCACCCATGGCAAATTCCATGGCA-3 0 , reverse: 5 0 -TCTAGACGGCAGGTCAGGTCCACC-3 0 . PCR products were resolved on 2% agarose gels, and visualized by staining with ethidium bromide. The results of 40 amplification cycles are shown. For the latter, we used the same primer pairs in the SYBR Green PCR system (Applied Biosystems, Foster City, CA, USA). Data quantification was carried out by the 2 ÀDDCt method (Pfaffl, 2001) .
